Edwards Lifesciences (XSWX:EW) Operating Income: CHF1,389 Mil (TTM As of Mar. 2026)


XSWX:EW Edwards Lifesciences Corp XSWX:EW
97 GF Score
Price CHF72.91
GF Value CHF75.73
! 5 Warning Signs
View Full Analysis

What is Edwards Lifesciences Operating Income?

Edwards Lifesciences XSWX:EW +0.37% 97 Operating Income is CHF1,389 Mil as of Mar. 2026. GuruFocus rates XSWX:EW with a GF Score™ of 97/100 and a GF Value™ of CHF75.73. The stock has 5 warning signs investors should review.

Edwards Lifesciences's Operating Income for the three months ended in Mar. 2026 was CHF405 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was CHF1,389 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Edwards Lifesciences's Operating Income for the three months ended in Mar. 2026 was CHF405 Mil. Edwards Lifesciences's Revenue for the three months ended in Mar. 2026 was CHF1,298 Mil. Therefore, Edwards Lifesciences's Operating Margin % for the quarter that ended in Mar. 2026 was 31.22%.

Warning Sign:

Edwards Lifesciences Corp operating margin has been in a 5-year decline. The average rate of decline per year is -2.9%.

Edwards Lifesciences's 5-Year average Growth Rate for Operating Margin % was -2.90% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Edwards Lifesciences's annualized ROC % for the quarter that ended in Mar. 2026 was 20.18%. Edwards Lifesciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 77.51%.


Edwards Lifesciences  (XSWX:EW) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Edwards Lifesciences's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=1620.892 * ( 1 - 17.06% )/( (6575.781 + 6745.823)/ 2 )
=1344.3678248/6660.802
=20.18 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=10915.299 - 971.58 - ( 3367.938 - max(0, 1445.338 - 5370.229+3367.938))
=6575.781

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=10487.781 - 851.386 - ( 2890.572 - max(0, 1109.306 - 4903.856+2890.572))
=6745.823

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Edwards Lifesciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1620.892/( ( (1525.745 + max(375.26, 0)) + (1513.506 + max(767.775, 0)) )/ 2 )
=1620.892/( ( 1901.005 + 2281.281 )/ 2 )
=1620.892/2091.143
=77.51 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(525.635 + 897.469 + 377.97) - (971.58 + 21.676 + 432.558)
=375.26

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(610.709 + 880.989 + 366.252) - (851.386 + 17.95 + 220.839)
=767.775

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Edwards Lifesciences's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=405.223/1297.943
=31.22 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Edwards Lifesciences Operating Income Related Terms


Edwards Lifesciences Operating Income Historical Data

* Premium members only.

The historical data trend for Edwards Lifesciences's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edwards Lifesciences Operating Income Chart

Edwards Lifesciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,461.44 1,433.83 1,285.27 1,319.66 1,303.89

Edwards Lifesciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 362.19 350.41 338.42 295.09 405.22
XSWX:EW
97GF Score
Edwards Lifesciences Corp XSWX:EW
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edwards Lifesciences Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF1,389 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of CHF1,389 Mil mean?
Edwards Lifesciences (XSWX:EW) has a Operating Income of CHF1,389 Mil as of Mar. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Edwards Lifesciences and its competitors.
Is Edwards Lifesciences' Operating Income too high?
Edwards Lifesciences' current Operating Income is CHF1,389 Mil. Overall, Edwards Lifesciences has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' Operating Income compare to DXCM and GEHC?
Edwards Lifesciences' Operating Income of CHF1,389 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Medical Devices & Instruments company?
A good Operating Income depends on the Medical Devices & Instruments industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Edwards Lifesciences and its competitors. Edwards Lifesciences's current Operating Income is CHF1,389 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Edwards Lifesciences (XSWX:EW) has a current Operating Income of CHF1,389 Mil. The stock's GF Value™ is CHF75.73, compared to a current price of CHF72.91 — trading 3.7% below its estimated fair value. The current Operating Income is CHF1,389 Mil. Edwards Lifesciences' overall GF Score™ is 97/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Edwards Lifesciences (XSWX:EW), the current Operating Income is CHF1,389 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Edwards Lifesciences (XSWX:EW) Overvalued in 2026?

Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued. The current stock price of CHF72.91 is trading 3.7% below its estimated GF Value™ of CHF75.73.

Key valuation signals for XSWX:EW:

  • Operating Income: CHF1,389 Mil
  • GF Value™: CHF75.73 vs. price of CHF72.91 (3.7% below fair value)
  • GF Score™: 97/100 with 5 warning signs

No single metric tells the full story. See the XSWX:EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Edwards Lifesciences Business Description

Address One Edwards Way, Irvine, CA, USA, 92614
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
97GF Score

Get the complete analysis for XSWX:EW

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF72.91
Price
CHF75.73
GF Value